Global Search | Novartis

Hide Filters

Showing 1244 results

Press release / Jul 07, 2015

Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization

First in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only treatment…
Press release / Jul 01, 2015

Alcon receives European Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery

AcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps to maintain the integrity of the incision while facilitating smooth, consistent delivery of the IOL…
Press release / Jun 30, 2015

Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches

New features of the ViaOpta apps, previously available for iPhone and AndroidTM mobile phones, are also available to enhance the daily lives of people with visual impairments These apps…
Press release / Jun 29, 2015

Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc.

Acquisition adds novel angiotensin II Type 2 receptor antagonist for the treatment of neuropathic pain to Novartis' industry-leading development pipeline Neuropathic pain is a chronic…
Press release / Jun 29, 2015

Novartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patients

In the FUTURE 2 study, secukinumab demonstrated rapid onset of action, was significantly superior to placebo in improving signs and symptoms of psoriatic arthritis (PsA), with efficacy sustained…
Press release / Jun 26, 2015

Novartis drug Farydak® recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of action

Farydak (panobinostat) combination improved PFS by 7.8 months for patients who received >=2 prior regimens including bortezomib and an IMiD[1] Farydak would be the first HDAC inhibitor with…
Press release / Jun 18, 2015

Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg

Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Sandoz has begun shipping to US customers…
Press release / Jun 18, 2015

Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day

Strong progress on innovation across divisions Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and…
Press release / Jun 16, 2015

Alcon receives European approval for new trifocal presbyopia-correcting intraocular lens for patients undergoing cataract surgery

Innovative AcrySof® IQ PanOptix® trifocal intraocular lens design to improve near to intermediate vision and increase independence from glasses More than three million cataract surgeries…
Press release / Jun 13, 2015

Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CML

Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of…